Background. In patients receiving continuous veno-venous haemofiltration (CVVH), there is little agreement regarding the most appropriate dosing regimen of meropenem, ranging from 500 mg every 12-24h to 2,000 mg every 8h. Meropenem is a time-dependent antibiotic and maintaining unbound drug concentrations above the minimum inhibitory concentration (MIC) of pathogen for at least 40% of the dosing interval is required for efficacy. Continuous (i.e., over 24 hours) or extended (EI, i.e., over a prolonged period of time of several hours during the dosing interval) infusions have been proposed to optimize pharmacokinetic/pharmacodynamic (PK/PD) properties, expecting improved clinical outcomes and decreased mortality, but CVVH was generally an exclusion criterion in these studies. The aim of this study was to compare the PK/PD of meropenem during intermittent infusion (II over 0.5 hours) or EI (over 3 hours) in critically ill patients receiving CVVH.
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Methods. Patients with severe nosocomial pneumonia and receiving CVVH, were treated prospectively with meropenem 1g every 8 hours either over II (n = 7) or over EI (n = 6). The ultrafiltration flow rate was adjusted to 30-35 ml/kg/hour. At steady state, we calculated the proportion of patients in each group achieving an optimal T > MIC (≥ 40% or 100% of the dosing interval) for 1, 4 and 5 -fold an MIC of 2mg/L which is the European Committee on Antimicrobial Susceptibility Testing (EUCAST) sensitivity breakpoint for Pseudomonas spp, Acinetobacter spp and Enterobacteriaceae.
Results. Concentrations were: ≥ 40% T ≥ 2 mg/L in 100% of patients for 1 X and 4 X the MIC in both groups and 85.7% vs 100% (P = 0.34) for 5 X the MIC in II and EI, respectively; and 100% T ≥ 2 mg/L for II and EI in 100% vs 100%, 42.9% vs 100% (P = 0.026) and 28.6% vs 100% (P = 0.0083) for 1 X, 4 X and 5 X the MIC, respectively.
Conclusion. In patients with severe nosocomial pneumonia and receiving CVVH with current ultrafiltration flow rates, the optimum regimen of meropenem was 1g infused over 3h every 8h. In this setting, EI offered better PK/PD parameters than II, particularly for a therapeutic goal of 100% T > 4 and 5 -fold an MIC of 2 mg/L.
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